A new trading day began on Friday, with Elevation Oncology Inc (NASDAQ: ELEV) stock price down -0.05% from the previous day of trading, before settling in for the closing price of $0.38. ELEV’s price has ranged from $0.22 to $3.09 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -25.69% over the last five years. Meanwhile, its annual earnings per share averaged 8.28%. With a float of $53.00 million, this company’s outstanding shares have now reached $59.22 million.
The firm has a total of 34 workers. Let’s measure their productivity. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Elevation Oncology Inc (ELEV) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Elevation Oncology Inc is 10.52%, while institutional ownership is 49.47%.
Elevation Oncology Inc (ELEV) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.12 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 8.28% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 17.27% during the next five years compared to -25.69% drop over the previous five years of trading.
Elevation Oncology Inc (NASDAQ: ELEV) Trading Performance Indicators
Here are Elevation Oncology Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 19.40.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.81, a number that is poised to hit -0.22 in the next quarter and is forecasted to reach -0.51 in one year’s time.
Technical Analysis of Elevation Oncology Inc (ELEV)
Analysing the last 5-days average volume posted by the [Elevation Oncology Inc, ELEV], we can find that recorded value of 0.82 million was lower than the volume posted last year of 1.89 million. As of the previous 9 days, the stock’s Stochastic %D was 51.76%.
During the past 100 days, Elevation Oncology Inc’s (ELEV) raw stochastic average was set at 40.71%, which indicates a significant decrease from 43.82% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.0092 in the past 14 days, which was lower than the 0.0272 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.3533, while its 200-day Moving Average is $0.4913. Now, the first resistance to watch is $0.3763. This is followed by the second major resistance level at $0.3775. The third major resistance level sits at $0.3801. If the price goes on to break the first support level at $0.3725, it is likely to go to the next support level at $0.3699. Should the price break the second support level, the third support level stands at $0.3687.
Elevation Oncology Inc (NASDAQ: ELEV) Key Stats
With a market capitalization of 22.21 million, the company has a total of 59,224K Shares Outstanding. Currently, annual sales are 0 K while annual income is -44,490 K. The company’s previous quarter sales were 0 K while its latest quarter income was -14,210 K.
